vs
COHEN & STEERS, INC.（CNS）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
COHEN & STEERS, INC.的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.9倍（$143.8M vs $75.5M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs 2.9%），PUMA BIOTECHNOLOGY, INC.自由现金流更多（$14.4M vs $-126.4M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 8.3%）
科恩斯蒂尔是一家美国投资管理企业，专注于通过房地产投资信托（REIT）开展不动产证券投资，同时布局优先证券相关的另类收益类投资业务，在全球不动产和另类收益投资领域拥有专业的运营经验。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
CNS vs PBYI — 直观对比
营收规模更大
CNS
是对方的1.9倍
$75.5M
营收增速更快
PBYI
高出24.8%
2.9%
自由现金流更多
PBYI
多$140.8M
$-126.4M
两年增速更快
PBYI
近两年复合增速
8.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $143.8M | $75.5M |
| 净利润 | $34.9M | — |
| 毛利率 | — | 69.3% |
| 营业利润率 | 28.0% | 22.7% |
| 净利率 | 24.3% | — |
| 营收同比 | 2.9% | 27.7% |
| 净利润同比 | -23.9% | — |
| 每股收益（稀释后） | $0.67 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CNSPBYI
| Q4 25 | $143.8M | $75.5M | ||
| Q3 25 | $141.7M | $54.5M | ||
| Q2 25 | $136.1M | $52.4M | ||
| Q1 25 | $134.5M | $46.0M | ||
| Q4 24 | $139.8M | $59.1M | ||
| Q3 24 | $133.2M | $80.5M | ||
| Q2 24 | $121.7M | $47.1M | ||
| Q1 24 | $122.7M | $43.8M |
净利润CNSPBYI
| Q4 25 | $34.9M | — | ||
| Q3 25 | $41.7M | $8.8M | ||
| Q2 25 | $36.8M | $5.9M | ||
| Q1 25 | $39.8M | $3.0M | ||
| Q4 24 | $45.8M | — | ||
| Q3 24 | $39.7M | $20.3M | ||
| Q2 24 | $31.8M | $-4.5M | ||
| Q1 24 | $34.0M | $-4.8M |
毛利率CNSPBYI
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% | ||
| Q1 24 | — | 75.5% |
营业利润率CNSPBYI
| Q4 25 | 28.0% | 22.7% | ||
| Q3 25 | 34.5% | 17.6% | ||
| Q2 25 | 31.8% | 12.7% | ||
| Q1 25 | 33.6% | 8.7% | ||
| Q4 24 | 35.3% | 22.6% | ||
| Q3 24 | 33.7% | 27.4% | ||
| Q2 24 | 31.5% | -4.6% | ||
| Q1 24 | 32.8% | -5.3% |
净利率CNSPBYI
| Q4 25 | 24.3% | — | ||
| Q3 25 | 29.4% | 16.2% | ||
| Q2 25 | 27.1% | 11.2% | ||
| Q1 25 | 29.6% | 6.5% | ||
| Q4 24 | 32.8% | — | ||
| Q3 24 | 29.8% | 25.2% | ||
| Q2 24 | 26.1% | -9.6% | ||
| Q1 24 | 27.7% | -11.0% |
每股收益（稀释后）CNSPBYI
| Q4 25 | $0.67 | $0.26 | ||
| Q3 25 | $0.81 | $0.17 | ||
| Q2 25 | $0.72 | $0.12 | ||
| Q1 25 | $0.77 | $0.06 | ||
| Q4 24 | $0.89 | $0.40 | ||
| Q3 24 | $0.77 | $0.41 | ||
| Q2 24 | $0.63 | $-0.09 | ||
| Q1 24 | $0.68 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $145.5M | $97.5M |
| 总债务越低越好 | — | $22.7M |
| 股东权益账面价值 | $562.0M | $130.3M |
| 总资产 | $876.7M | $216.3M |
| 负债/权益比越低杠杆越低 | — | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资CNSPBYI
| Q4 25 | $145.5M | $97.5M | ||
| Q3 25 | $98.1M | $94.4M | ||
| Q2 25 | $95.4M | $96.0M | ||
| Q1 25 | $65.2M | $93.2M | ||
| Q4 24 | $183.0M | $101.0M | ||
| Q3 24 | $106.5M | $96.7M | ||
| Q2 24 | $122.0M | $96.8M | ||
| Q1 24 | $99.5M | $107.2M |
总债务CNSPBYI
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
股东权益CNSPBYI
| Q4 25 | $562.0M | $130.3M | ||
| Q3 25 | $550.3M | $115.3M | ||
| Q2 25 | $528.5M | $104.7M | ||
| Q1 25 | $507.7M | $97.1M | ||
| Q4 24 | $511.7M | $92.1M | ||
| Q3 24 | $491.0M | $71.1M | ||
| Q2 24 | $463.2M | $48.5M | ||
| Q1 24 | $378.9M | $51.0M |
总资产CNSPBYI
| Q4 25 | $876.7M | $216.3M | ||
| Q3 25 | $801.6M | $202.9M | ||
| Q2 25 | $751.0M | $194.9M | ||
| Q1 25 | $834.9M | $196.2M | ||
| Q4 24 | $812.4M | $213.3M | ||
| Q3 24 | $727.8M | $220.7M | ||
| Q2 24 | $784.1M | $205.0M | ||
| Q1 24 | $680.7M | $214.1M |
负债/权益比CNSPBYI
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-120.4M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | $-126.4M | $14.4M |
| 自由现金流率自由现金流/营收 | -87.9% | 19.1% |
| 资本支出强度资本支出/营收 | 4.2% | 0.0% |
| 现金转化率经营现金流/净利润 | -3.45× | — |
| 过去12个月自由现金流最近4个季度 | $-253.6M | $41.7M |
8季度趋势，按日历期对齐
经营现金流CNSPBYI
| Q4 25 | $-120.4M | $14.4M | ||
| Q3 25 | $55.1M | $9.7M | ||
| Q2 25 | $-67.6M | $14.1M | ||
| Q1 25 | $-108.9M | $3.6M | ||
| Q4 24 | $96.7M | $15.6M | ||
| Q3 24 | $25.6M | $11.0M | ||
| Q2 24 | $31.4M | $1.0M | ||
| Q1 24 | $4.9M | $11.2M |
自由现金流CNSPBYI
| Q4 25 | $-126.4M | $14.4M | ||
| Q3 25 | $52.6M | $9.7M | ||
| Q2 25 | $-69.8M | $14.1M | ||
| Q1 25 | $-110.0M | $3.6M | ||
| Q4 24 | $85.0M | $15.6M | ||
| Q3 24 | $24.2M | $11.0M | ||
| Q2 24 | $27.1M | $1.0M | ||
| Q1 24 | $537.0K | — |
自由现金流率CNSPBYI
| Q4 25 | -87.9% | 19.1% | ||
| Q3 25 | 37.1% | 17.7% | ||
| Q2 25 | -51.3% | 26.8% | ||
| Q1 25 | -81.8% | 7.7% | ||
| Q4 24 | 60.8% | 26.4% | ||
| Q3 24 | 18.2% | 13.7% | ||
| Q2 24 | 22.3% | 2.1% | ||
| Q1 24 | 0.4% | — |
资本支出强度CNSPBYI
| Q4 25 | 4.2% | 0.0% | ||
| Q3 25 | 1.8% | 0.0% | ||
| Q2 25 | 1.6% | 0.0% | ||
| Q1 25 | 0.8% | 0.1% | ||
| Q4 24 | 8.3% | 0.0% | ||
| Q3 24 | 1.1% | 0.0% | ||
| Q2 24 | 3.5% | 0.0% | ||
| Q1 24 | 3.5% | 0.0% |
现金转化率CNSPBYI
| Q4 25 | -3.45× | — | ||
| Q3 25 | 1.32× | 1.10× | ||
| Q2 25 | -1.84× | 2.41× | ||
| Q1 25 | -2.74× | 1.21× | ||
| Q4 24 | 2.11× | — | ||
| Q3 24 | 0.65× | 0.54× | ||
| Q2 24 | 0.99× | — | ||
| Q1 24 | 0.14× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
